18,715 Shares in Biogen Inc. (NASDAQ:BIIB) Bought by Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD

Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD acquired a new position in shares of Biogen Inc. (NASDAQ:BIIB) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 18,715 shares of the biotechnology company’s stock, valued at approximately $2,860,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in BIIB. State Street Corp increased its stake in Biogen by 3.5% in the 3rd quarter. State Street Corp now owns 7,344,960 shares of the biotechnology company’s stock valued at $1,423,747,000 after buying an additional 248,942 shares during the last quarter. Geode Capital Management LLC increased its stake in Biogen by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 3,613,020 shares of the biotechnology company’s stock valued at $698,062,000 after buying an additional 47,055 shares during the last quarter. Pacer Advisors Inc. increased its stake in Biogen by 13,574.7% in the 4th quarter. Pacer Advisors Inc. now owns 2,667,531 shares of the biotechnology company’s stock valued at $407,919,000 after buying an additional 2,648,024 shares during the last quarter. Amundi increased its stake in Biogen by 35.6% in the 4th quarter. Amundi now owns 1,216,990 shares of the biotechnology company’s stock valued at $183,461,000 after buying an additional 319,478 shares during the last quarter. Finally, RA Capital Management L.P. increased its stake in Biogen by 20.6% in the 3rd quarter. RA Capital Management L.P. now owns 1,184,456 shares of the biotechnology company’s stock valued at $229,595,000 after buying an additional 202,317 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Biogen Trading Down 4.7 %

NASDAQ BIIB opened at $143.66 on Wednesday. The company has a quick ratio of 0.90, a current ratio of 1.35 and a debt-to-equity ratio of 0.27. Biogen Inc. has a twelve month low of $128.51 and a twelve month high of $238.00. The company has a market cap of $21.03 billion, a price-to-earnings ratio of 12.84, a price-to-earnings-growth ratio of 1.51 and a beta of 0.01. The business’s fifty day moving average is $143.80 and its 200 day moving average is $165.37.

Biogen (NASDAQ:BIIB) last announced its earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 EPS for the quarter, topping the consensus estimate of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.87%. As a group, sell-side analysts expect that Biogen Inc. will post 15.83 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently commented on BIIB shares. Mizuho decreased their price objective on shares of Biogen from $251.00 to $207.00 and set an “outperform” rating for the company in a research report on Thursday, November 21st. Royal Bank of Canada decreased their price objective on shares of Biogen from $231.00 to $225.00 and set an “outperform” rating for the company in a research report on Thursday, February 13th. StockNews.com downgraded shares of Biogen from a “strong-buy” rating to a “buy” rating in a research report on Saturday, December 28th. Jefferies Financial Group downgraded shares of Biogen from a “buy” rating to a “hold” rating and decreased their price objective for the company from $250.00 to $180.00 in a research report on Monday, December 9th. Finally, Bank of America reissued a “neutral” rating and issued a $178.00 price objective on shares of Biogen in a research report on Tuesday, December 10th. Seventeen research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $213.33.

Insider Transactions at Biogen

In related news, Director Stephen A. Sherwin sold 8,760 shares of the business’s stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $150.02, for a total value of $1,314,175.20. Following the completion of the sale, the director now directly owns 11,318 shares of the company’s stock, valued at $1,697,926.36. The trade was a 43.63 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.16% of the company’s stock.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.